Further trials are investigating anti-PD-1/L1 administration in other cancers such as lung [90], bladder[91–93], renal cancers[74, 94], breast[95–96] and chemotherapy-refractory Hodgkin disease[78]. This evidence concerns the gene PDCD1 and cancer.